10-Year Study Involving 500 Women Yields Promising Results
Team HS
Study published in the Lancet has given a new rays of hopes to patients and healthcare professionals as a new A treatment plan for cervical cancer has proven to slashing mortality rates by 40%, according to a Lancet study.
Researchers said that while most cervical cancer patients are in their 30s, despite improvements in care, the cancer returns in as many as 30% of the cases.
However the researchers studied the new treatment for 10 years in patients from the UK, Mexico, India, Italy and Brazil. A combination of chemotherapy and radiotherapy, building upon the established standard treatment for cervical cancer.
During the phase-three clinical trial, 40 per cent reduces in mortality rate from cervical cancer was seen by the scientists from University College London. Moreover 35 per cent risk of cancer coming back within five years were also reduced.
With 6,60,000 new cases and 3,50,000 deaths due to cervical cancer reported in 2022, the scientists believe a revolutionary short-term treatment plan, poised to significantly enhance survival prospects for patients battling locally advanced cervical cancer.
Although using a combination of chemotherapy and radiation cervical cancers can be treated locally, but still most of patients experience the cancer spreading and don’t survive.
However researchers investigated whether initiating chemotherapy prior to standard chemoradiotherapy could improve patient survival rate, prevent cancer progression and enhance treatment efficacy
A groundbreaking cervical cancer trial involving 500 women has yielded promising results. Participants, whose tumors had not spread to other organs, were randomly assigned to receive either a pioneering treatment plan or standard chemoradiation therapy. This comprehensive study aimed to evaluate the novel approach’s efficacy, compare outcomes with traditional treatment, and assess safety.
Participants received a novel treatment regimen: a six-week induction course of carboplatin and paclitaxel chemotherapy, subsequently combined with concurrent standard radiotherapy, weekly cisplatin administration and intracavitary brachytherapy.
The control group, however, received only the usual chemoradiation treatment.
Meanwhile study also revealed remarkable five-year survival rates for cervical cancer patients. Those receiving initial chemotherapy showed 80% overall survival and 72% cancer-free status, outperforming standard treatment results (72% survival, 64% cancer-free)
The overall survival rate showed a 40% relative reduction in the risk of dying from cervical cancer.
“This study establishes a novel standard of care for locally advanced cervical cancer: short-course induction chemotherapy followed by chemoradiotherapy within 7 days, yielding improved survival outcomes. Clinical guidelines should be updated to reflect the efficacy of short-course induction chemotherapy paired with swift chemoradiotherapy for locally advanced cervical cancer, enhancing patient outcomes,” the authors of the study wrote.
